In this study, based on the ADJUVANT-CTONG 1104 trial, we profiled the TCR repertoire of patients with an EGFR mutation with early-stage NSCLC and explored the predictive value of TCRβ clones for the different outcomes of the patients in the trial. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.